- Home
- SRRK vs PTEN Comparison
SRRK vs PTEN Comparison
Compare SRRK & PTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- PTEN
- Stock Information
- Founded
- SRRK 2012
- PTEN 1978
- Country
- SRRK United States
- PTEN United States
- Employees
- SRRK N/A
- PTEN N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- PTEN Oil & Gas Production
- Sector
- SRRK Health Care
- PTEN Energy
- Exchange
- SRRK Nasdaq
- PTEN Nasdaq
- Market Cap
- SRRK 2.8B
- PTEN 3.0B
- IPO Year
- SRRK 2018
- PTEN 1993
- Fundamental
- Price
- SRRK $26.49
- PTEN $8.04
- Analyst Decision
- SRRK Strong Buy
- PTEN Buy
- Analyst Count
- SRRK 7
- PTEN 14
- Target Price
- SRRK $34.00
- PTEN $12.04
- AVG Volume (30 Days)
- SRRK 984.5K
- PTEN 9.6M
- Earning Date
- SRRK 11-12-2024
- PTEN 10-23-2024
- Dividend Yield
- SRRK N/A
- PTEN 3.98%
- EPS Growth
- SRRK N/A
- PTEN N/A
- EPS
- SRRK N/A
- PTEN N/A
- Revenue
- SRRK N/A
- PTEN $5,800,093,000.00
- Revenue This Year
- SRRK N/A
- PTEN $33.99
- Revenue Next Year
- SRRK N/A
- PTEN N/A
- P/E Ratio
- SRRK N/A
- PTEN N/A
- Revenue Growth
- SRRK N/A
- PTEN 73.11
- 52 Week Low
- SRRK $6.76
- PTEN $7.38
- 52 Week High
- SRRK $35.38
- PTEN $12.65
- Technical
- Relative Strength Index (RSI)
- SRRK 50.87
- PTEN 48.20
- Support Level
- SRRK $25.86
- PTEN $8.19
- Resistance Level
- SRRK $28.11
- PTEN $8.57
- Average True Range (ATR)
- SRRK 1.68
- PTEN 0.34
- MACD
- SRRK -0.92
- PTEN 0.04
- Stochastic Oscillator
- SRRK 11.71
- PTEN 47.83
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
About PTEN Patterson-UTI Energy Inc.
Patterson-UTI Energy is one of the largest land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. It also provides directional drilling services and tool rental services in most US onshore oil and gas basins.